1-(1-氧代-2-吡啶基)-哌嗪 | 337956-36-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(1-氧代-2-吡啶基)-哌嗪
• 英文名称: 1-(1-oxido-2-pyridinyl)piperazine
• 英文别名: 1-(1-oxy-pyridin-2-yl)-piperazine；1-((pyridin N-oxide)-2-yl)-piperazine；1-(N-Oxido-2-pyridyl)piperazin；1-(1-oxidopyridin-1-ium-2-yl)piperazine
• CAS: 337956-36-2
• 化学式: C₉H₁₃N₃O
• 分子量: 179.222
• InChiKey: JSBDZSPMYPEPGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  40.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-硝基水杨酸 、 1-(1-氧代-2-吡啶基)-哌嗪 在 bromotripyrrolidinophosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 二氯甲烷 、 H₂₀ 为溶剂， 以65%的产率得到2-(4-(2-hydroxy-3-nitrobenzoyl)piperazin-1-yl)pyridine 1-oxide
  参考文献：
  名称：

  3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

  摘要：

  这里公开了用于治疗诸如急性和慢性炎症性疾病以及癌症的趋化因子介导疾病的公式1化合物或其药用可接受的盐或溶剂。

  公开号：

  US20040106794A1
• 作为产物：
  描述：

  tert-butyl 4-(1-oxidopyridin-1-ium-2-yl)piperazine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.5h， 以33%的产率得到1-(1-氧代-2-吡啶基)-哌嗪
  参考文献：
  名称：

  3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

  摘要：

  这里公开了用于治疗诸如急性和慢性炎症性疾病以及癌症的趋化因子介导疾病的公式1化合物或其药用可接受的盐或溶剂。

  公开号：

  US20040106794A1

文献信息

• Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
  申请人：Cowart D. Marlon

  公开号：US20060172995A1

  公开（公告）日：2006-08-03

  The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein A, L, D and B, are as described in the specification.

  本发明涉及使用公式(I)化合物的用途，用于治疗性功能障碍，以及包含用于治疗性功能障碍的公式(I)化合物的组合物，其中A、L、D和B如说明书中所述。
• [EN] FUSED BICYCLIC AROMATIC COMPOUNDS THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION<br/>[FR] COMPOSES AROMATIQUES BICYCLIQUES CONDENSES UTILES DANS LE TRAITEMENT DE DYSFONCTIONNEMENT SEXUEL
  申请人：ABBOTT LAB

  公开号：WO2003101994A1

  公开（公告）日：2003-12-11

  The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

  本发明涉及使用化合物(I)的治疗性功能障碍，并涉及含有化合物(I)的组合物用于治疗性功能障碍。
• Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction
  申请人：Cowart D. Marlon

  公开号：US20070265249A1

  公开（公告）日：2007-11-15

  The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein A, L, D and B 1 are as described in the specification.

  本发明涉及使用式（I）化合物治疗性功能障碍以及含有式（I）化合物的组合物治疗性功能障碍，其中A、L、D和B1如说明书所述。
• Optimized pyridazinone nutrient channel inhibitors are potent and specific antimalarial leads
  作者：Michelle M Butler、Samanthi L. Waidyarachchi、Jinfeng Shao、Son T. Nguyen、Xiaoyuan Ding、Steven C. Cardinale、Lucas R. Morin、Steven M. Kwasny、Mai Ito、Jeanine Gezelle、Maria B. Jiminez-Di­az、Inigo Angulo-Barturen、Robert T. Jacobs、Jeremy N. Burrows、Zachary D. Aron、Terry L. Bowlin、Sanjay A. Desai

  DOI：10.1124/molpharm.122.000549

  日期：——

  Human and animal malaria parasites increase their host erythrocyte permeability to a broad range of solutes as mediated by parasite-associated ion channels. Molecular and pharmacological studies have implicated an essential role in parasite nutrient acquisition, but inhibitors suitable for development of antimalarial drugs are missing. Here, we generated a potent and specific drug lead using Plasmodium falciparum , a virulent human pathogen, and derivatives of MBX-2366, a nanomolar affinity pyridazinone inhibitor from a high-throughput screen. As this screening hit lacks the bioavailability and stability needed for in vivo efficacy, we synthesized 315 derivatives to optimize drug-like properties, establish target specificity, and retain potent activity against the parasite-induced permeability. Using a robust, iterative pipeline, we generated MBX-4055, a derivative active against divergent human parasite strains. MBX-4055 has improved oral absorption with acceptable in vivo tolerability and pharmacokinetics. It also has no activity against a battery of 35 human channels and receptors and is refractory to acquired resistance during extended in vitro selection. Single-molecule and single-cell patch-clamp indicate direct action on the plasmodial surface anion channel, a channel linked to parasite-encoded RhopH proteins. These studies identify pyridazinones as novel and tractable antimalarial scaffolds with a defined mechanism of action. SIGNIFICANCE STATEMENT Because antimalarial drugs are prone to evolving resistance in the virulent human P. falciparum pathogen, new therapies are needed. This study has now developed a novel drug-like series of pyridazinones that target an unexploited parasite anion channel on the host cell surface, display excellent in vitro and in vivo ADME properties, are refractory to acquired resistance, and demonstrate a well defined mechanism of action.

  人类和动物疟原虫寄生虫通过寄生虫相关离子通道，增加宿主红细胞对多种溶质的通透性。分子和药理学研究表明，寄生虫营养获取过程中寄生虫发挥着重要作用，但适合开发抗疟药物的抑制剂尚未出现。在此，我们使用恶性疟原虫（一种致命的人类病原体）和MBX-2366衍生物（一种从高通
• Structure−Activity Relationship Study on <i>N</i>-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a Class of 5-HT₇ Receptor Agents. 2
  作者：Marcello Leopoldo、Enza Lacivita、Marialessandra Contino、Nicola A. Colabufo、Francesco Berardi、Roberto Perrone

  DOI：10.1021/jm070487n

  日期：2007.8.1

  Here we report the synthesis of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides 16-29 that were designed to elucidate both structure-affinity and -activity relationships for the 5-HT7 receptor, by targeting the substituent in 2-position of the aryl linked to the piperazine ring. The affinities of 16-29 for 5-HT7, 5-HT1A, 5-HT2A, and D-2 receptors were assessed by radioligand binding assays. The intrinsic activities at the 5-HT7 receptor of the most potent compounds were determined. A series of substituents covering a wide range of electronic, steric, and polar properties was evaluated, revealing a key role on 5-HT7 receptor affinity and intrinsic activity. Certain lipophilic substituents (SCH3, CH(CH3)(2), N(CH3)(2), CH3, Ph) led to high-affinity agonists, whereas OH and NHCH3 substituents switched intrinsic activity toward antagonism. 4-[2-(1-Methylethyl)phenyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (19), 4-(2-diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (21), and 4-(2-dimethylaminophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (22) were identified as potent 5-HT7 receptor agonists (K-i = 0.13-1.1 nM, EC50 = 0.90-1.77 mu M), showing selectivity over 5-HT1A, 5-HT2A, and D-2 receptors.